NCT05498961 is a clinical trial of Gallstone characteristics in Acute Gallstone Pancreatitis, sponsored by Hepatopancreatobiliary Surgery Institute of Gansu Province.

Who is sponsoring NCT05498961?

NCT05498961 is sponsored by Hepatopancreatobiliary Surgery Institute of Gansu Province.

What drugs are being tested in NCT05498961?

Interventions in NCT05498961: Gallstone characteristics.

What condition does NCT05498961 study?

NCT05498961 studies Acute Gallstone Pancreatitis.

Is NCT05498961 still recruiting?

NCT05498961 is currently completed. Last updated 26 September 2023.

Last reviewed 2023-09-26 · How we verify

NCT05498961

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Gallstone Characteristics for the Severity of Gallstone Pancreatitis

Completed Last updated 26 September 2023

What this trial tests

trial testing Gallstone characteristics in Acute Gallstone Pancreatitis in 301 participants. Completed in 24 September 2023.

Timeline

10 August 2022

Primary endpoint
24 September 2023

24 September 2023

Quick facts

Lead sponsor	Hepatopancreatobiliary Surgery Institute of Gansu Province
Status	Completed
Study type	OBSERVATIONAL
Enrollment	301
Start date	10 August 2022
Primary completion	24 September 2023
Estimated completion	24 September 2023
Sites	1 location across China

Drugs / interventions tested

Gallstone characteristics

Conditions studied

Acute Gallstone Pancreatitis — all drugs for Acute Gallstone Pancreatitis →

Sponsor

Hepatopancreatobiliary Surgery Institute of Gansu Province

Who can join

Adults 18 to 90, any sex, with Acute Gallstone Pancreatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to determine the effect of gallstone characteristics for the severity of acute gallstone pancreatitis (GSP)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Early prediction of acute gallstone pancreatitis severity: a novel machine learning model based on CT features and open access online prediction platform.
Ma Y, Yue P, Zhang J, Yuan J, et al · · 2024 · cited 6× · PMID 38813815 · DOI 10.1080/07853890.2024.2357354

Verify or expand the search:

Other Hepatopancreatobiliary Surgery Institute of Gansu Province trials

Trials by the same sponsor.

NCT03104569 — Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma · NA · not yet recruiting
NCT07321431 — The Optimal Measurement Time for the New Gallbladder Function Assessment Method · NA · recruiting
NCT07091526 — Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer · recruiting
NCT07039864 — A Novel Strategy for Evaluating Gallbladder Contraction Function by Ultrasound · NA · completed
NCT06697405 — Impact of Cardiopulmonary Bypass Time on Gastrointestinal Complications · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05498961 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hepatopancreatobiliary Surgery Institute of Gansu Province
Last refreshed: 26 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05498961.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing